However, the anti-CCR4 mAb therapy induces several serious adverse effects, including Stevens–Johnson syndrome/toxic epidermal necrolysis, when normal CCR4+ Tregs are attacked [31–33]. The gene discussed is CCR4; the disease is toxic epidermal necrolysis.